MELBOURNE, Australia, 19 October, 2016: AdAlta Limited (ASX: 1AD), the biotechnology company focused on advancing its lead i-body candidate towards clinical development today announced Chief Executive Officer Sam Cobb will be presenting at and attending a number of key forthcoming conferences to raise awareness with potential investors and partners.
• Australian Microcap Investment Conference, 18-19 October, Melbourne, Australia
Company presentation on 19 October 2016 at 11:45am at the Sofitel Melbourne, Australia
• AusBiotech 2016, 24 – 26 October, Melbourne, Australia
Company attending the Ausbiotech conference and will be available for partnering discussions and will also participate on the Victorian Government BioIndustry Exhibition Booth at AusBiotech on Wednesday 26th October 2016, 8:30am-3:30pm at Melbourne Convention Centre.
• Australia Biotech Invest, 26 – 27 October, Melbourne, Australia
Company presentation on 26 October 2016 at 1:30pm at Melbourne Convention Centre
• BioEurope, 7 – 9 November, Cologne, Germany
Company attending and will be available for partnering discussions
• BiotechShowcase, 9 – 11 January 2017, San Francisco, USA
Company presenting during the conference at the Hilton, San Francisco, USA
A copy of the presentations made by AdAlta’s CEO at Australian Microcap Investment Conference, Ausbiotech and Australia Biotech Invest have been previously released to ASX and a copy is available on the Company’s website.
AdAlta Limited is an Australian based drug development company headquartered in Melbourne. The Company is focused on using its proprietary technology platform to generate i-bodies, a new class of protein therapeutics, with applications as therapeutic drugs to treat disease.
The i-body is a human analogue of the antigen binding domain of the shark antibody, which combines the advantages of monoclonal antibodies (high target specificity and affinity) with the beneficial stability features of small molecules. In addition to stability, the i-body has a long binding loop that is a feature of shark antibodies not present in either human or next generation antibodies. This feature enables the i-body to recognise and bind to a diverse range of different therapeutically-relevant drug targets, including those that are difficult/intractable to access by current antibody therapies. These include clinically important targets such as G-protein coupled receptors (GPCRs) and ion channels.
AdAlta is developing its lead i-body candidate, AD-114, for the treatment of idiopathic pulmonary fibrosis (IPF) and other human fibrotic diseases, for which current therapies are sub-optimal and there is a high-unmet medical need.
The Company also plans to continue further drug discovery and development directed towards other drug targets and diseases with its i-body technology platform.
Issued for and on behalf of Avita Medical by Instinctif Partners.
Further information can be found at: www.adalta.com.au
At the Company
Chief Executive Officer
Tel: +61 (0) 3 9479 5159
Sue Charles/Daniel Gooch
Tel: +44 (0) 20 7866 7905